NatroVital - Purity Is Our Priority


Your Cart is Empty

Health Article References

Is Low GABA Why I Feel The Way I Do?

We have listed all references noted below for the health article Is Low GABA Why I Feel The Way I Do? for your convenience below.

  1. Shimada, M., et al. Anti-hypertensive effect of gamma-aminobutyric acid (GABA)-rich Chlorella on high-normal blood pressure and borderline hypertension in placebo-controlled double blind study. Clin Exp Hypertens. 31(4):342-354, 2009
  2. Abdou, A. M., et al. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 26(3):201-208, 2006
  3. Shell, W., et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther. 17(2):133-139, 2010
  4. Head, K. A., et al. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Alternative Medicine Review. 14(2), 2009
  5. Nakagawa, T., et al. Protective effects of gamma-aminobutyric acid in rats with streptozotocin-induced diabetes. J Nutr Sci Vitaminol (Tokyo). 51(4):278-282, 2005
  6. During, M. J., et al. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 341(8861):1607-1610, 1993
  7. Bhagwagar, Z., et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol. 11:1-6, 2007
  8. Backstrom, T., et al. Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci. 1007:42-53, 2003
  9. Loeb, C., et al. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Research. 1(3):209-212, 1987
  10. Goddard, A. W., et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 58(6):556-561, 2001
  11. Monograph: Gamma-aminobutyric acid (GABA). Alternative Medicine Review. 12(3):274-279, 2007
  12. Epperson, C. N., et al. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl). 186(3):425-433, 2006
  13. Ito, K., et al. GABA-synthesizing enzyme, GAD67, from dermal fibroblasts: evidence for a new skin function. Biochim Biophys Acta. 2006

The Natural Way To Increase GABA

These references are noted on our health article The Natural Way To Increase GABA

  1. Abdou, A. M., et al. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors. 26(3):201-208, 2006.
  2. Shell, W., et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther. 17(2):133-139, 2010.
  3. Head, K. A., et al. Nutrients and botanicals for treatment of stress: adrenal fatigue, neurotransmitter imbalance, anxiety, and restless sleep. Alternative Medicine Review. 14(2), 2009.
  4. Breier, A., et al. The GABA-A/Benzodiazepine receptor: implications for the molecular basis of anxiety. Journal of Psychiatric Research. 24(Supplement 2):91-104, 1990.
  5. Nemeroff, C. B., et al. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 37(4):133-146, 2003.
  6. El Idrissi, A.. Taurine improves learning and retention in aged mice. Neurosci Lett. 2008.
  7. Molchanova, S. M., et al. Effect of taurine on the concentrations of glutamate, GABA, glutamine and alanine in the rat striatum and hippocampus. Proc West Pharmacol Soc. 50:95-97, 2007.
  8. Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system I. Central depressant effect of theanine. Chem Pharm Bull. 19:1257–1261, 1971.
  9. Nathan, P. J., et al. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother. 6(2):21-30, 2006.
  10. Chen, S. W., et al. Possible anxiolytic effects of taurine in the mouse elevated plus-maze. Life Sciences. 75(12):1503-1511, 2004.
  11. Kong, W. X., et al. Effects of taurine on rat behaviors in three anxiety models. Pharmacol Biochem Behav. 2006.
  12. Heese, T., et al. Anxiolytic effects of L-theanine - a component of green tea - when combined with midazolam, in the male Sprague-Dawley rat. AANA J. 77(6):445-449, 2009.
  13. Ito, K., et al. Effects of L-theanine on the release of alpha brain waves in human volunteers. Nippon Nogeikagaku Kaishi. 72:153-157, 1998.
  14. Lu, K., et al. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol. 19(7):457-465, 2004.
  15. 17th European Sleep Research Society Congress. Prague. October 2004.
  16. Kimura, K., et al. l-Theanine reduces psychological and physiological stress responses. Biol Psychol. 74(1):39-45, 2007.
  17. Dolu, N., et al. Dose-related anxiogenic effect of glycine in the elevated plus maze and in electrodermal activity. J Basic Clin Physiol Pharmacol. 18(2):141-147, 2007.
  18. Prousky, J. E. Orthomolecular treatment of anxiety disorders. Townsend Letter for Doctors and Patients. February-March 2005.
  19. Nicoll, R. A. Introduction to the pharmacology of CNS drugs. In: Katzung, B. G. (editor), Basic & Clinical Pharmacology (sixth edition). Prentice-Hall International, London. 1995:323-332.
  20. In-Tele-Health © 2009 (from Hyperhealth Pro CD-ROM)
  21. Amsterdam, J. D., et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 29(4):378-382, 2009.
  22. Viola, H., et al. Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica. 61(3):213-216, 1995.
  23. Yamada, K, et al. Effect of inhalation of chamomile oil vapour on plasma ACTH level in ovariectomized rats under restriction stress. Biol Pharm Bull. 19(9):1244-1246, 1996.
  24. Shinomiya, K., et al. Hypnotic activities of chamomile and passiflora extracts in sleep-disturbed rats. Biol Pharm Bull. 28(5):808-810, 2005.
  25. Roberts, A., et al. The effect of olfactory stimulation on fluency, vividness of imagery and associated mood: a preliminary study. Br J Med Psychol. 65(2):197-199, 1992.
  26. Felter HW, Lloyd J you: King's American dispensary, ED 18, Rev 3, Portland, 1905, reprinted 1983, Eclectic Medical Publications.
  27. Krenn, L. [Passion Flower (Passiflora incarnata L.) - a reliable herbal sedative.] Wien Med Wochenschr. 152(15-16):404-406, 2002.
  28. Akhondzadeh, S., et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxezepam. J Clin Pharm Ther. 26(5):363-367, 2001.
  29. Brown, E., et al. Evaluation of the anxiolytic effects of chrysin, a Passiflora incarnata extract, in the laboratory rat. AANA J. 75(5):333-337, 2007.
  30. Dhawan, K., et al. Anxiolytic activity of aerial and underground parts of Passiflora incarnata. Fitoterapia. 72(8):922-926, 2001.
  31. Capasso, A., et al. Pharmacological studies on the sedative and hypnotic effect of Kava kava and Passiflora extracts combination. Phytomedicine. 12(1-2):39-45, 2005.
  32. Soulimani, R., et al. Behavioural effects of Passiflora incarnata L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. Journal of Ethnopharmacology. 57(1):11-20, 1997.
  33. Deng, S., et al. Noni as an anxiolytic and sedative: a mechanism involving its gamma-aminobutyric acidergic effects. Phytomedicine. 2007.
  34. Li, Y. F., et al. Antistress effect of oligosaccharides extracted from Morinda officinalis in mice and rats. Acta Pharmacol Sin. 22(12):1084-1088, 2001.
  35. Einat, H., et al. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord. 62(1-2):113-121, 2001.
  36. Barkai, A. I., et al. Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psych. 13(1):65-72, 1978.
  37. Benjamin, J. et al. Inositol treatment in psychiatry. Psychopharmacol Bull. 31:167-175, 1995.
  38. Colodny, L., et al. Inositol - clinical applications for exogenous use. Alternative Medicine Review. 3(6):432-447, 1998.
  39. Einat, H., et al. Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology. 144(2):158-162, 1999.
  40. Nick, G. L. Inositol as a treatment for psychiatric disorders: a scientific evaluation of its clinical effectiveness. Townsend Letter for Doctors and Patients. October 2004.
  41. Head, K. A. Premenstrual syndrome: nutritional and alternative approaches. Alternative Medicine Review. 2(1):12-25, 1997.
  42. Ah Kang-Yoon, S., et al. Relation of short-term pyridoxine-hydrochloride supplementation to plasma vitanin-B6 vitamers and amino acid concentrations in young women. American Journal of Clinical Nutrition. 55(4):865-872, 1992.
  43. Visual textbook of nutritional medicine by Dr Igor Trabrizian ISBN 0–975 6920–5–4.
  44. Grases, G., et al. Anxiety and stress among science students. Study of calcium and magnesium alterations. Magnesium Research. 19(2):102-106, 2006.
  45. Hanus, M., et al. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin. 20(1):63-71, 2004.
  46. Taborska, V. [Incidence of latent tetany in patients with panic disorder]. Cesk Psychiatr. 91(3):183-190, 1995.
  47. Morris, M. E. Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: neurological symptoms. Magnesium Research. 5(4):303-313, 1992.
  48. Saris, N.-E. L., et al. Magnesium: an update on physiological, clinical and analytical aspects. Clinica Chimica Acta. 294:1-26, 2000.
  49. Tanabe, K., et al. Erythrocyte magnesium and prostaglandin dynamics in chronic sleep deprivation. Clin Cardiol. 20(3):265-268, 1997.
  50. Webb, W. L., et al. Electrolyte and fluid imbalance: Neuropsychiatric manifestations. Psychosomatics. 22(3):199-203, 1981.
  51. Jacka, F. N., et al. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry. 43(1):45-52, 2009.
  52. Frizel, D., et al. Plasma calcium and magnesium in depression. British Journal of Psychiatry. 115(529):1375-1377, 1969.
  53. Chollet, D., et al. Blood and brain magnesium in inbred mice and their correlation with sleep quality. Am J Physiol Regul Integr Comp Physiol. 279(6):R2173-R2178, 2000.
  54. Poleszak, E., et al. Benzodiazepine/GABA(A) receptors are involved in magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep. 60(4):483-489, 2008.
  55. Crofts, S. L., et al. Anxiety before operation and serum potassium. Anaesthesia. 45(12):1101-1102, 1990.
  56. McCleane, G. J., et al. Pre-operative anxiety and serum potassium. Anaesthesia. 45(7):583-585, 1990.
  57. Cox, J. R., et al. Changes in sodium, potassium and fluid spaces in depression and dementia. Gerontology Clin. 13:232-245, 1971.
  58. 58. Drennan, M. D., et al. Potassium affects actigraph-identified sleep. Sleep. 14(4):357-360, 1991.
  59. Jobin Mathew,Savitha Balakrishnan, Sherin Antony, Pretty Mary Abraham, and CS Paulose; Decreased GABA receptor in the cerebral cortex of epileptic rats: effect ofBacopa monnieriand Bacoside-A: J Biomed Sci. 2012; 19(1): 25.
  60. Hoosain SJ, Aoshima H, Kiso Y. fragrances in oolong tea that enhance the response of GABA A receptors. Biosci Biotechnol Biochem. 2004 Sep;68(9): 1842 – 8.
  61. Cho YR, Chang JY, Chang HC. Production of GABA byte Lactobacillus buchneri isolated from kimchi and its neuro protective effect on neuron cells J Microbiol Biotechnol. 2007 Jan;17(1):104-9
  62. Inoue K, Shirai T, Ochiai H, Kassao M, Hayakawa K, Kimura M, Sansawa H. Blood pressure lowering effect of a novel fermented milk containing in mild hypertensives. J Clin Nutr. 2003 Mar; 57 (3):490-5
  63. Kim JY, Lee MY, Ji GE, Lee YS, Hwang KT. Reduction of GABA black raspberry juice during fermentation by Lactobacillus brevis. Int J Food Microbiol. 2009 Mar 15;130 (1):12-6.
  64. LI Y, Bai Q, Jin X, Wen H, Gu Z. Effects of cultivar and culture conditions on GABA accumulation in germinated fava beans. J Sci Food Argric. 2010 Jan 15;90(1):52-7
  65. Akihiro T, Koike S, Tani R, Tominaga T, Watanabe S, Iijima Y, Aoki K, Shibata D, Ashihara H, Matsukura C, Akama K, Fujimura T, Ezura H. Biochemical mechanisms of GABA accumulation during fruit development in tomato. Plant Cell Physiol. 2008 Sept;49(9): 1378-89.
  66. Kathiresan A, Tung P, Chinnappa CC, Reid DM. GABA stimulate ethylene biosynthesis in sunflower. Plant Physiol. 1997 Sept; 115 (1):129-35
  67. Avallone R, Zanoli P, Corsi L, Cannazza G, Baraldi M. Benzodiazepine compounds and GABA in flower heads of matricaria chamomilla. Phytotherapy Res. 1996;10:177–179.
  68. Albrecht J, Bender AS, Norenberg MD. Potassium-stimulated GABA release is a chloride-dependent but sodium- and calcium-independent process in cultured astrocytes. Acta Neurobiol Exp (Wars). 1998;58(3):169-75.
  69. Wang DS, Xu TL, Li JS. 5-HTP potentiates GABA- and glycine-activated chloride currents on the same neurons in rat spinal cord. J Hirnforsch. 1999;39(4):531-7.
  70. Sasaki, K., et al. Effects of chronic administration of bilobalide on amino acid levels in mouse brain. Cell Mol Biol. 48(6):681-684, 2002.
  71. Houghton, P. J. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol. 51(5):505-512, 1999.
  72. Ortiz, J. G., et al. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res. 24(11):1373-1378, 1999.
  73. Trauner, G., et al. Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Medica. 74(1):19-24, 2008
  74. Santos, M. S., et al. Synaptosomal GABA release as influenced by valerian root extract--involvement of the GABA carrier. Arch Int Pharmacodyn. 327(2):220-231, 1994.
  75. Muller, W. E., et al. Hyperforin - antidepressant activity by a novel mechanism of action. Pharmacopsychiatry. 34(Supplement 1):S98-S102, 2001.
  76. Jussofie A, Schmiz A, Hiemke C., et al. Psychopharmacology (Berl). Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. 1994 Dec;116(4):469-74.
  77. Holm E, et al. Arzneimittelforschung 1991 Jul;41(7):673-683.
  78. Sarris J,McIntyre E,Camfield DA. Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs. 2013 Apr;27(4):301-19. 

Is Leaky Gut Syndrome Leaving You Feeling Unwell?

These references are noted on our health article Is Leaky Gut Syndrome Leaving You Feeling Unwell?

  1. Sung Hee Lee: Intestinal Permeability Regulation by Tight Junction: Implication on Inflammatory Bowel Diseases Intest Res. 2015 Jan; 13(1): 11–18.
  2. Mark E. M. Obrenovich, Leaky Gut, Leaky Brain? Microorganisms. 2018 Dec; 6(4): 107.
  3. Alessandro Attanzio, Luisa Tesoriere, Sonya Vasto, Anna Maria Pintaudi, Maria A. Livrea, and Mario Allegra. Short-term cactus pear [Opuntia ficus-indica (L.) Mill] fruit supplementation ameliorates the inflammatory profile and is associated with improved antioxidant status among healthy humans. Food Nutr Res. 2018; 62: 10.29219/fnr.v62.1262.
  4. Sofia Moran-Ramos, Xuan He, Elizabeth L. Chin, Armando R. Tovar, Nimbe Torres, Carolyn M. Slupsky, and Helen E. Raybould; Nopal feeding reduces adiposity, intestinal inflammation and shifts the cecal microbiota and metabolism in high-fat fed rats. PLoS One. 2017; 12(2): e0171672.
  5. Erika Utzeri, Paolo Usai. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Jun 14; 23(22): 3954–3963.
  6. Julia König, Jerry Wells, Patrice D Cani, Clara L García-Ródenas, Tom MacDonald, Annick Mercenier, Jacqueline Whyte, Freddy Troost, and Robert-Jan Brummer. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016 Oct; 7(10): e196.

Is Pyroluria or Pyrrole Disorder Getting You Down? 

These references are noted on our health article Is Pyroluria or Pyrrole Disorder Getting You Down?

  1. Pfeiffer CC, Iliev V. Pyroluria, urinary mauve factor, cases double deficiency of B6 and zinc in schizophrenics. Fed Am Soc Exp Biol. 1973;32:276.
  2. Pfeiffer CC, Sholer A, Jenny EH, et al. Treatment of pyroluric schizophrenia with large doses of pyridoxine and a dietary supplement of zinc. J Appl Nut. 1974;26:21-28.
  3. Pfeiffer CC, Bacchi D, copper, zinc, manganese niacin and pyridoxine in schizophrenia J Appl Nutr. 1975;27:9-39.
  4. Pfeiffer CC. Mental and elemental nutrients. New Canaan, CT: Keats publishing 1976.
  5. Pfeiffer CC. The schizophrenia’s ’76. Biol Psychiatry. 1976;11(6):773-775. Pfeiffer CC. Extra nutrients and mental illness. Biol Psychiatry. 1981;16(9):797-799
  6. Pfeiffer CC, Holford P. Mental Illness and Schizophrenia: The Nutritional Connection. Harper Collins Publishers, Great Britain;1987.
  7. Pfeiffer CC. Nutrition and Mental Illness: An Orthomolecular Approach to Balancing Body Chemistry. Rochester, VT: Healing Arts Press;1987.
  8. Kruesi O. Low plasma biotin levels in high mauve patients. Oral Communication 2005
  9. Discercing the mauve factor, part 1: Alt Theapies, Mar/Apr 2008. Vol.14, No.2
  10. Rohweder J, Runkel N, Fromm M, Schulzke JD, Buhr HJ. Zinc acts a protective agent on the mucosal barrier in experimental TNBS colitis [in German]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl 1):223-227.
  11. Rodriguez P, Darmon N, Chappuis P, et al. Intestinal paracellular permeability during malnutrition in guinea pigs: effect of high dietary zinc. Gut. 1996;39(3):416-422.
  12. Sturniolo GC, Fries W, Mazzon E, Di Leo V, Barollo M, D’inca R. Effect of zinc supple- mentation on intestinal permeability in experimental colitis. J Lab Clin Med. 2002;139(5):311-315.
  13. Mahmood A, Fitzgerald AJ, Marchbank T, et al. Zinc carnosine, a health food supple- ment that stabilizes small bowel integrity and stimulates gut repair processes. Gut. 2007;56(2):168-175. Epub 2006 Jun 15.
  14. Bates CJ, Evans PH, Dardenne M, et al. A trial of zinc supplementation in young rural Gambian children. Br J Nutr. 1993;69(1):243-255.
  15. Chen P, Soares AM, Lima AA, et al. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil. J Health Popul Nutr. 2003;21(4):309-315.
  16. Sturniolo GC, Di Leo V, Ferronato A, D’Odorico A, D’Incà R. Zinc supplementation tightens “leaky gut” in Crohn’s disease. Inflamm Bowel Dis. 2001;7(2):94-98.
  17. Irvine DG. Kryptopyrrole in molecular psychiatry. In: Hawkins D, Pauling L, eds. Orthomolecular Psychiatry: Treatment of Schizophrenia. San Francisco: WH Freeman and Company; 1973:146-178.
  18. Sakurai E, Fukuse G, Ueda M, Murata R, Hikichi N, Niwa H. Alteration of biogenic amines, serotonin, histamine and polyamines, in cases of diarrhea induced by various cathartics [in Japanese]. Nippon Yakurigaku Zasshi. 1980;76(5):293-299.
  19. Farack UM, Nell G. Mechanism of action of diphenolic laxatives: the role of adenylate cyclase and mucosal permeability. Digestion. 1984;30(3):191-194.
  20. Schmelzer M, Schiller LR, Meyer R, Rugari SM, Case P. Safety and effectiveness of large-volume enema solutions. Appl Nurs Res. 2004;17(4):265-274.
  21. Hart A, Kamm MA. Review article: mechanisms of initiation and perpetuation of gut inflammation by stress. Ailment Pharmacol Ther. 2002;16(12):2017-2028.
  22. Martínez-Augustín O, Sánchez de Medina F Jr, Sánchez de Medina F. Effect of psycho- genic stress on gastrointestinal function. J Physiol Biochem. 2000;56(3):259-274.
  23. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol. 2005;20(3):332-339.
  24. Irvine DG. Mauve factor and 6-sulfatoxy skatole: two biochemical abnormalities asso- ciated with specific measures of psychiatric disease. Clin Chem. 1963;9:444-445.
  25. Chen C, Lyte M, Stevens MP, Vulchanova L, Brown DR. Mucosally-directed adrenergic nerves and sympathomimetic drugs enhance non-intimate adherence of Escherichia coli O157:H7 to porcine cecum and colon. Eur J Pharmacol. 2006;539(1-2):116-124.
  26. Corwin A M, et al. Encylopaedia Britannica 1960;18:801
  27. Atamna H, Killilea DW, Killilea AN, Ames BN. Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. Proc Nat Acad Sci U S A. 2002;99(23):14807-14812.
  28. Atamna H. Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev. 2004;(3)3:303-318.
  29. Lill R, Kispal G. Maturation of cellular Fe-S proteins: an essential function of mitochon- dria. Trends Biochem Sci. 2000;25(8):352-356.
  30. Graham DJM, Thompson GG, Moore MR, Goldberg AA. The effects of selected monopyrroles on various aspects of heme biosynthesis and degradation in the rat. Arch Biochem Biophys. 1979;65(1):132-138.
  31. Ames BN, Atamna H, Killilea DW. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. Mol Aspects Med. 2005;26(4-5):363-378.
  32. Cabrini L, Bergami R, Fiorentini D, Marchetti M, Landi L, Tolomelli B. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int.1998;46(4):689-697. 107.
  33. Park LC, Zhang H, Sheu KF, et al. Metabolic impairment induces oxidative stress, com-promises inflammatory responses, and inactivates key mitochondrial enzyme in micro-glia. J Neurochem. 1999;72(5):1948-1958. 108.
  34. Atamna H, Walter PB, Ames BN. The role of heme and iron-sulfur clusters in mito-chondrial biogenesis, maintenance, and decay with age. Archiv Biochem Biophys.2002;397(2):345-353.
  35. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involve- ment in schizophrenia pathophysiology: a review [in French]. Encephale. 2006;32(2 Pt 1):244-252.
  36. Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and mem-brane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disor-der patients. Psychiatry Res. 2003;121(2):109122.
  37. Zoroglu SS, Armutcu F, Ozen S, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry ClinNeurosci. 2004;254(3):143-147.
  38. Liu S, Kawai K, Tyurin VA, et al. Nitric oxide-dependent pro-oxidant and pro-apoptoticeffect of metallothioneins in HL-60 cells challenged with cupric nitrilotiracetate.Biochem J. 2001;354(pt 2):397-406.
  39. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Path. 1999;9(1):69-92.
  40. Shinkai T, Ohmori O, Hori H, Nakamura J. Allelic association of the neuronal nitricoxide synthatse (NOS1) gene with schizophrenia. Mol Psychiatry. 2002;7(6):560-563.
  41. Sögüt S, Zoroglu SS, Ozyurt H, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved inautism. Clin Chim Acta. 2003;331(1-2):111-117.
  42. De la Monte SM, Bloch KD. Aberrant expression of the constituitive endothelial nitricoxide synthase gene in Alzheimer disease Mol Chem Neuropathol. 1997;30(1-2):139-159.
  43. Ward JL. Relationship of kryptopyrrole, zinc and pyridoxine in schizophrenics. JOrthomolec Psychiatr. 1975;4:27-31.
  44. Discerning the Mauve Factor by Woody R. McGinnis MD, Tapan Audhya Ph.D. and William J Walsh Ph.D.